With two approved drugs and close to 300 clinical / preclinical product candidates, By Roots Analysis Knowpia

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html

The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:

§ Therapeutic Area

Autoimmune Disorders
Eye Disorders
Genetic Disorders
Hematological Malignancies
Infectious Diseases
Inflammatory Disorders
Skin Disorders

§ Mechanism of Action

Cytokines Retargeting / Neutralization
Dual Ligands Blocking
T-cell Retargeting / Activation
Others

§ Target Antigens

CD3 x CD19
CD30 x CD16A
Factor IXa x Factor X
IL-1α x IL-1β
IL-13 x IL-4
IL-17A x Albumin
IL-17A x IL-17F
Psl x PcrV
VEGF-A x ANG2
Others

§ Antibody Formats

Asymmetric
Fragments
Symmetric
Others

§ Key Geographical Regions

North America
Europe
Asia-Pacific

The Bispecific Antibody Therapeutics Market (4^th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

§ Amgen

§ Ablynx

§ AbbVie

§ Affibody

§ Affimed

§ Alphamab

§ AstraZeneca

§ Avillion

§ Chugai Pharmaceuticals

§ Eddingpharm

§ GSK

§ Merck